Curadev under its CSR program, sponsored the Impact India’s 172nd Lifeline Express (World’s First Hospital Train) project at Gondia in Maharashtra from May 4 to 25, 2016. The aim of the Lifeline Express is to deliver quality medical and surgical services in rural and remote areas of our country.
Dr. David Cameron Pryde appointed Director, R&D of Curadev UK
Dr. David Pryde has joined Curadev as Director R&D bringing his extensive experience in drug discovery to the team. Prior to joining Curadev, Dr. Pryde was at Pfizer for 19 years and led the medicinal chemistry component of programs in several target classes. Dr. Pryde is the author of numerous research publications and patents. He has an honors degree in chemistry from the University of Strathclyde, did his doctoral research at the University of Nottingham and post-doctoral work at Colorado State University. He is also a member of the Royal Society of Chemistry, the organizing committee of the Society for Medicines Research and holds CChem and FRSC status.
American Association for Cancer Research meeting in New Orleans
Curadev and Roche jointly author poster titled: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.